Ex parte MCVAY et al. - Page 4




          Appeal No. 95-2022                                                          
          Application No. 08/063,056                                                  


               its fairness is evidenced by the PTO's inability to                    
               manufacture products or to obtain and compare prior art                
               products.  [Footnote and citations omitted.]                           
          On these facts, we believe that the burden of persuasion shifted            
          to appellants "to prove that the prior art products do not                  
          necessarily or inherently possess the characteristics of [their]            
          claimed product."  This appellants have not done.  In the absence           
          of a showing, it appears that the evaporated black liquor                   
          described by Forss, EXAMPLE 10, like the product defined in                 
          claims 31 and 32, comprises molecules which pass through an                 
          ultrafiltration membrane having a molecular weight cut-off of               
          about 50,000 and are rejected by an ultrafiltration membrane                
          having a molecular weight cut-off of about 2,000.                           
               For these reasons, we find that (1) the examiner established           
          a prima facie case of anticipation of claims 31 and 32 based on             
          the description in Forss, EXAMPLE 10; and (2) appellants have not           
          rebutted the prima facie case.  We therefore affirm the rejection           
          of independent claims 31 and 32 under 35 U.S.C. § 102(b) as                 
          anticipated by Forss.  In so doing, we are mindful that                     
          appellants rely on data presented in their specification and in             
          the McVay declaration, executed July 12, 1993, designed to show             
          that their claimed product possesses unexpectedly superior                  
          results.  See the Appeal Brief, section VI.C.  We point out,                
          however, that a proper rejection under 35 U.S.C. § 102 cannot be            
                                         -4-                                          




Page:  Previous  1  2  3  4  5  6  7  8  9  Next 

Last modified: November 3, 2007